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Abstract
Background: Frailty and cognitive impairment are seemingly distinct syndromes, but have a shared vulnerability to
stress in older adults, resulting in poorer outcomes. Although there has been recent interest in cognitive frailty,
frailty transitions in relation to cognitive deterioration in older adults with cognitive impairment have not yet been
well studied. We thus aim to study frailty transitions and change in cognitive status over 1-year follow-up among
subjects with cognitive impairment attending a tertiary Memory Clinic.
Methods: This is a prospective cohort study of mild cognitive impairment (MCI) and mild-moderate Alzheimer’s
disease (AD) community-dwelling subjects. We obtained data on clinical measures, muscle mass and physical
performance measures. Cognitive status was measured using Chinese Mini-Mental State Examination (CMMSE) and
Clinical Dementia Rating-Sum of Boxes (CDR-SB) scores. We measured gait speed, hand grip strength, exhaustion
and weight loss at baseline, 6 and 12 months to classify subjects according to the modified Fried criteria (involving
strength, gait speed, body composition and fatigue) into non-frail (<2 frail categories) and frail categories (≥2 frail
categories). Frailty transitions between baseline and 12-months were assessed. We performed random effects statistical
modelling to ascertain baseline predictors of longitudinal frailty scores for all subjects and within MCI subgroup.
Results: Among 122 subjects comprising 41 MCI, 67 mild and 14 moderate AD, 43.9, 35.8 and 57.1 % were frail at
baseline respectively. Frailty status regressed in 32.0 %, remained unchanged in 36.0 %, and progressed in 32.0 % at
12 months. Random effects modelling on whole group showed longitudinal CDR-SB scores (coeff 0.09, 95 %
confidence interval (CI) 0.03–0.15) and age (coeff 0.04, 95 % CI 0.02–0.07) to be significantly associated with
longitudinal frailty score. Among MCI subjects, only female gender (coeff 1.28, 95 % CI 0.21–2.36) was associated with
longitudinal frailty score, while mild-moderate AD subjects showed similar results as those of the whole group.
Conclusions: This is the first study to show longitudinal frailty state transitions in cognitively-impaired older adults.
Frailty transitions appear to be independent of progression in cognitive status in earliest stages of cognitive
impairment, while mild-moderate AD subjects showed associations with age and cognitive deterioration. The
potential for cognitive frailty as a separate therapeutic entity for future physical frailty prevention requires further
research with a suitably powered study over a longer follow-up period.
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Background
Research efforts over the past decade have focused on
defining the clinical and physiological characteristics of
frailty and its relationship to adverse health outcomes [1,
2]. The relative lack of concrete data on the relationship
between cognition and neurodegeneration in mediating
frailty progression, has fuelled calls for more research
into this area [3]. Recent research has focused on the
proposed entity of “cognitive frailty” [4, 5] to describe a
clinical condition that is characterized by simultaneous
occurrence of physical frailty and cognitive impairment
in the absence of overt dementia. This potentially could
be a preventive or therapeutic target to prevent both
cognitive and functional decline, and frailty progression.
Many cross-sectional studies demonstrated the rela-
tionship between general cognitive function and physical
frailty [6], although less consistently with dementia [7].
Sub-domains of gait speed and grip strength appear to
be more strongly associated with cognitive function, in
contrast to the association of executive function with
frailty [6, 8]. Additionally, Alzheimer’s disease (AD)
pathology is associated with physical frailty [9]. Con-
versely, physical frailty has been associated with incident
mild cognitive impairment (MCI) and Alzheimer’s demen-
tia, and greater rate of cognitive decline in older persons
[10, 11]. The surge of transition studies in recent years
have mainly focused on physical frailty [12–15], with a
relative paucity of data available for concomitant transi-
tions in cognitive status. A recent cross-sectional study
suggests a U-shaped relationship between frailty and
cognition, characterized by initial dissociation with cog-
nitive impairment and subsequent convergence at later
stages [16].
Frailty among older persons have been shown to be a
dynamic process, characterized by frequent transitions
between frailty states over time [15, 17]. Despite the
interest in the area, most of the studies have looked at
transition in frailty and health status using multistate
modelling methods employing deficit counts [14, 18, 19].
More recent studies have highlighted age, medical fac-
tors [12, 20] and higher socioeconomic status to be pro-
tective [12]. Only one published study has looked at
baseline cognition scores and frailty to be strongly asso-
ciated with changes in cognitive status over time in the
Canadian Study of Health and Aging (CSHA) study [21].
Functional deterioration constitutes the most signifi-
cant contributor to informal and formal costs of demen-
tia care [22]. Despite recent advances in understanding
the pathophysiology of AD and numerous drug trials, ef-
fective interventions to prevent or delay functional de-
cline in dementia remain elusive It has been suggested
that cognitive frailty might represent the earliest
spectrum of the clinical entity [4, 5]. Because frailty rep-
resents a separate therapeutic target for dementia
subjects, cognitive frailty may thus present a potential
window of opportunity for targeted interventions to
delay overt functional decline and disability. A deeper
understanding of the trajectory and predictors of frailty
transitions across the different stages of AD could allow
further investigation into different stage-specific patho-
genic mechanisms akin to the different biomarker stages
in AD pathology [23], thus allowing for targeted inter-
ventions to delay functional decline and disability.
Thus, in this prospective study of community-dwelling
older adults with different stages of cognitive impair-
ment from MCI through to mild-moderate AD stages,
we aim to study the relationship between frailty transi-
tions and change in cognitive status over one year.
Methods
This is a prospective cohort study of MCI and mild-
moderate probable AD community-dwelling subjects at-
tending a specialist Memory Clinic, Cognition and
Memory Disorders Service, Tan Tock Seng Hospital,
Singapore between the period of December 2010 to
December 2014. Ethics approval was obtained from the
Domain Specific Review Board (DSRB) of the National
Healthcare Group (NHG). Written consent was obtained
from the patient or legally acceptable representative
where appropriate.
Study groups
MCI was defined as: (a) global Clinical Dementia Rating
(CDR) [24] score of 0.5; (b) subjective memory com-
plaint which is corroborated by a reliable informant; (c)
delayed recall >1 SD below age and education-adjusted
means derived from an earlier normative study [25]; (d)
relatively normal general cognitive function (Chinese
Mini Mental State Examination (CMMSE) [26] score ≥
21 and ≥ 24 for subjects with ≤6 and >6 years education
respectively; and (e) largely intact activities of daily liv-
ing; and [6] no clinical dementia.
Mild-moderate AD subjects fulfill diagnoses of prob-
able AD using the National Institute of Neurological and
Communicative Disorders and Stroke and Alzheimer’s
Disease and Related Disorders Association (NINCDS-
ADRDA) criteria) [27] and had a global CDR score of
0.5–2.0 respectively. We excluded subjects with a diag-
nosis of possible AD.
Inclusion and exclusion criteria
Subjects are eligible if they fulfilled the following: age ≥
55 years; diagnosis of MCI or mild to moderate AD;
availability of a reliable informant; and community
dwelling. We excluded subjects with presence of other
central nervous conditions (stroke disease, Parkinson’s
disease, subdural hematoma, normal pressure hydro-
cephalus, and brain tumor), presence of systemic
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conditions that can contribute to CI (hypothyroidism,
B12 deficiency, and hypercalcaemia), presence of any ac-
tive neuropsychiatric conditions producing disability,
and residence in a sheltered or nursing home. Grip
strength exclusions included recent pain in the wrist or
hand or a history of surgery on the upper extremity in
the 3 months preceding assessment.
The validity of the overall cognitive evaluation process
and CDR scoring has been previously established [24, 28].
Laboratory investigations excluding potentially reversible
causes of dementia via blood tests and neuroimaging were
done. A multidisciplinary consensus meeting was con-
ducted to review all relevant results for accurate clinical
phenotyping. Patients meeting study eligibility were then
included in the study.
Baseline data collection
Demographics, cognitive and functional assessment
We collected data on: (a) baseline demographics (age,
gender, years of education); (b) general cognitive func-
tion (CMMSE); (c) dementia severity (CDR global and
sum-of-boxes (CDS-SB) score) [24]; (d) physical func-
tioning (Barthel’s basic activities of daily living (ADL)
index [29] and Lawton’s instrumental ADL (iADL) index
[30]); and (e) behavioral symptoms using the Neuro-
psychiatric Inventory (NPI) [31] and the Diagnostic and
Statistical Manual, 4th ed (DSM-IV) for Major Depres-
sion [32]. MCI subjects also underwent a neuropsycho-
logical assessment that evaluated amnestic (immediate,
delayed and recognition verbal memory) and non-
amnestic (language, attention, executive function and
visuospatial function) domains [23].
Vascular risk factor profile
Data on hypertension, hyperlipidemia, diabetes mellitus,
atrial fibrillation, peripheral vascular disease, smoking
history, ischemic heart disease, and body mass index
were collected. Multi-morbidity was calculated based on
summation of the above factors (excluding BMI) (max-
imum score of 7).
Neuroimaging
Brain computed tomography (CT) scan or magnetic res-
onance imaging (MRI) was performed. White matter le-
sions (WML) severity was graded using the Age-Related
White Matter Changes (ARWMC) scale by a blinded
rater (L.T.) [33]. Medial temporal atrophy (MTA) score
(reflecting neurodegeneration) was scored on T1-
weighted coronal slices parallel to the brainstem axis
and perpendicular to the hippocampal axis, by a consen-
sus method where the scores range from 0 (no atrophy)
to 4 (severe atrophy) [34].
Frailty and related nutritional and activity measurements
A single blinded assessor (Y.R) measured the four com-
ponents of grip strength, timed walk, unintentional
weight loss (>3 kg) and fatigue to yield a modified Fried
criteria [1], which is better operationalized in the clin-
ical setting. The frailty scoring was done by a separate
assessor (CMS). Grip strength was measured using the
hydraulic hand dynamometer (North Coast@ Hydraulic
Hand Dynamometer). Two trials of grip strength were
obtained for each hand with all 4 trials averaged to
yield a final strength score. Gait speed was based on
the time taken to walk 15 ft (4.5 m). Published Asian
cut-offs were used to define each frailty sub-item (grip
strength <26 kg for males and <18 kg for females
scored as 1; and gait speed <0.8 m/s scored as 1) [35].
Lastly, we modified 2 questions from the Center for
Epidemiologic Studies-Depression Scale to assess fa-
tigue. Participants answered yes/no to the following: (a)
I felt that everything I did was an effort, and (b) I could
not get “going”. The frailty sub-item of fatigue was con-
sidered positive if either question was endorsed. A sub-
ject was classified as frail if the summated sub-item
scores were ≥ 2 and non-frail if <2. The rationale for
the 4 categories and exclusion of physical activity was
based on Buchmann data [10] for AD. Physical activity
of subjects were obtained by way of Frenchay activity
scale [36].
Nutrition was assessed using the Mini Nutritional
Assessment (MNA) questionnaire [37].
Muscle mass measurements
Muscle mass (lean and fat mass of upper and lower ex-
tremity and percentage body fat) was measured via Dual
energy X-ray absorptiometry (DXA) Hologic machine
Discovery Series APEX 13.3-Model. DXA currently rep-
resents the more accessible technique for body compos-
ition assessment. It accurately provides estimates of lean,
fat, and bone tissues in the entire body or in specific re-
gions. The coefficient of variation (CV) is 0.39 %. Ap-
pendicular Skeletal mass (ASM)/ht2 was calculated by
the summation of muscle mass measured in the four
limbs divided by square of height (in metres). The Short
Physical Performance Battery (SPPB) [38] was used to
measure physical performance.
Vitamin D, lipid status and APOE genotyping
We measured total 25-hydroxy vitamin D level with the
CV at 17.8ug/L was 7.2 %. Fasting total cholesterol,
high-density lipoprotein (HDL) level, low-density lipo-
protein (LDL) and triglyceride (TG) levels were obtained
from the participants. Apolipoprotein E (APOEε4) is a
plasma cholesterol transport molecule which has been
postulated to be associated with AD. Importantly,
APOEε4 status may exert a modulatory effect on disease
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trajectory and clinical expression of disease. We per-
formed APOE genotyping into APOEε2, 3, 4 isoforms
via restriction enzyme analysis using applied biosystems
platform- ABI Prism 310 Genetic Analyser.
6 and 12-month data collection
Frailty and cognitive measures were collected at baseline,
6 and 12-month follow-up period.
Frailty transitions were defined based on differences in
frailty scores between baseline and 12 months, with de-
crease (≥ −1 point), unchanged (0 point) or increase (≥1
point) corresponding to regressed, unchanged and pro-
gressed frailty states respectively.
Statistical analyses
We performed univariate analysis to examine differ-
ences in baseline characteristics between the 3 cogni-
tive subgroups (MCI, mild AD and moderate AD),
using analysis of variance (ANOVA) with Bonferroni
correction for parametric continuous variables (as con-
firmed by normality testing) and Kruskal-Wallis test for
nonparametric continuous variables. Chi-square test
was performed for categorical variables among the 3
cognitive subgroups. Similarly, we performed univariate
analyses to compare baseline characteristics among the
three frailty transition subgroups (regressed, un-
changed, and progressed).
We performed random effects modelling with longitu-
dinal frailty score as the dependent variable. We in-
cluded a-priori defined covariates-including age, gender,
cognition-related, functional measures, biochemical and
lifestyle factors for the frailty outcome. We subsequently
repeated analyses separately for MCI subjects and mild-
moderate AD subjects.
Statistical analyses was performed on STATA 13.0
statistical software and statistical significance taken to
be p < 0.05.
Results
Among 163 eligible subjects, 41 declined to participate
in the study (10 MCI and 31 mild AD subjects). Thus,
there were 122 subjects in our final sample, comprising
41 MCI, 67 mild AD and 14 moderate AD. The reasons
given were refusal by their caregiver or legally acceptable
representative and concerns regarding blood draw.
There were no age or gender differences between sub-
jects who accepted or decline participation in the study.
Of the 122 patients, the mean age was 75.4 ± 7.2 years
and 40.6 % were male (Table 1). They were predomin-
antly of Chinese ethnicity with mean education of 7.1 ±
5.0 years.
Comparison of demographics, vascular risk profile,
cognitive and functional status between 3 cognitive
subgroups
There were significant differences between the cognitive
subgroups in terms of female preponderance 56.1, 34.3
and 21.4 % male, p < 0.05) and smoking history (19.4,
13.4 and 14.2 %, p < 0.05) between MCI, mild and mod-
erate AD subjects respectively. As expected, cognitive
and functional performance (in terms of ADL and iADL)
were significantly different among the cognitive sub-
groups. Activity as measured on Frenchay Activity Index
decreased with increasing cognitive impairment (28.1 ±
6.9, 21.6 ± 6.6, 13.8 ± 6.9 respectively), as did hand grip
strength (22.7 ± 8.2, 18.3 ± 6.8, 16.3 ± 5.9 respectively)
and SPPB performance (9.7 ± 2.3, 8.9 ± 2.0), 6.5 ± 2.4 re-
spectively) (all p < 0.05) (see Table 1).
Comparison between frailty state transitions and
longitudinal cognitive performance (Fig. 1)
In the overall group, 41.0 % were frail at baseline,
37.6 % frail at 6 months and 43.4 % frail at 12 months.
The prevalence of frailty in MCI, mild and moderate AD
cognitive subgroups to vary between the 6-month inter-
vals (presented as proportions; 0.36 (95 % confidence
interval (CI) (0.15–0.64) vs 0.35 (95 % CI 0.24–0.48) vs
0.50 (95 % CI 0.23–0.77) at baseline; 0.29 (95 % CI 0.11–
0.58) vs 0.37 (95 % CI 0.25–0.49) vs 0.50 (95 % CI 0.23–
0.77) at 6 months and 0.21 (95 % CI 0.07–0.51) vs 0.44
(95 % CI 0.32–0.57) vs 0.67 (95 % CI 0.36–0.88) at
12 months for MCI, mild and moderate AD respectively)
while CMMSE scores for MCI, mild and moderate AD
follow a predictable linear pattern of cognitive decline
(25.2 ± 3.4 vs 18.4 ± 4.6 vs 13.3 ± 5.4 at baseline, and
25.0 ± 2.4 vs 17.8 ± 5.1 vs 11.0 ± 6.3 at 12-month for
MCI, mild and moderate AD respectively) [30].
Frailty status progression
As a whole group, 39 subjects (32 %) had frailty regres-
sion, 44 (36 %) remained unchanged while 39 (32 %)
progressed during the one-year follow-up. Notably,
among cognitive subgroups, the majority of MCI sub-
jects either regressed (31.7 %) or remained unchanged
(41.5 %) in frailty status, whereas mild and moderate AD
tended to progress (47.8 and 50.0 % respectively) al-
though these observed differences did not reach statis-
tical significance on chi-squared test (p = 0.20) (Fig. 2).
Comparison of patient factors between 3 frailty transition
status (Table 2)
Baseline cognitive status on CMMSE and CDR-SB
were not significantly different in the 3 frailty transition
groups, nor did baseline measures of neurodegeneration
and white matter lesions on MTA and ARWMC. Signifi-
cant univariate differences were noted in smoking status,
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Table 1 Patient baseline demographics, vascular risk profile, cognitive and functional status among 3 cognitive subgroups (MCI,
mild AD and moderate AD)
Total (n = 122) MCI (n = 41) Mild AD (n = 67) Moderate AD (n = 14)
Demographics
Age 75.4 (7.2) 72.5 (7.1) 76.3 (6.9) 79.4 (6.1)
Gender (Male %) 40.6 56.1 34.3 21.4 *
Race (Chinese %) 94.3 92.6 94.0 100
Education years 7.1 (5.0) 9.9 (4.7) 5.8 (4.6) 4.9 (4.5)
CDR global 0.9 (0.5) 0.5 (0.1) 0.9 (0.3) 1.82 (0.5)*a,b,c
CDR Sum of boxes 4.0 (3.0) 1.1 (0.6) 4.7 (1.8) 9.2 (2.7)*a,b,c
CMMSE 20.1 (5.7) 25.2 (2.3) 18.4 (4.6) 13.4 (5.4)*a,b,c
Medical comorbidities
HT (%) 65.5 58.5 68.7 71.4
DM (%) 29.5 24.4 35.8 14.3
Hyperlipidemia (%) 70.5 63.4 74.6 71.4
IHD (%) 21.3 26.8 17.9 21.4
Smoker/ex-heavy smoker (%) 15.5 19.4 13.4 14.2 *
AF (%) 3.3 2.4 4.5 0
PVD (%) 0.8 2.4 0 0
Multimorbidity score 2.1 (1.2) 2.0 (1.3) 2.1 (1.2) 1.9 (1.3)
BMI 22.9 (3.2) 23.1 (2.6) 22.8 (3.6) 22.8 (2.4)
ETOH ingestion (%) 12.2 18.2 10.4 7.1
Past psy problem (%) 4.9 9.8 1.5 7.1
MDD (%) 2.5 4.9 1.5 0
Neurodegeneration and wm scores
APOE status
E2/e2 0.8 0 1.5 0
E2/e3 12.3 17.1 7.5 21.4
E2/e4 1.6 2.4 1.5 0
E3/e3 47.5 46.3 52.2 28.6
E3/e4 32.8 29.3 31.3 50.0
E4/e4 4.9 4.9 6.0 0
MTA score 1.2 (1.0) (n = 106) 0.6 (0.8) (n = 38) 1.5 (1.0) (n = 59) 1.6 (1.0) (n = 9)
ARWMC score 4.9 (4.2) (n = 117) 4.2 (3.3) (n = 38) 5.0 (4.8) (n = 65) 6.4 (3.6) (n = 14)
Function, behaviour and burden scores
ADL 97.8 (5.7) 99.1 (1.9) 97.8 (5.5) 93.9 (11.1)*a,b
iADL 15.7 (5.4) 19.7 (3.7) 14.4 (4.7) 10.4 (4.7)*a,b,c
NPI total severity 2.1 (1.7) 1.4 (1.3) 2.3 (1.8) 2.9 (1.7)*b,c
NPI CG distress 3.6 (5.3) 1.4 (2.6) 4.1 (5.6) 7.2 (6.7)*b,c
Zarit total 22.6 (16.1) 20.3 (15.7) 21.7 (14.7) 29.6 (21.5)
FAI total 22.9 (8.1) 28.2 (6.9) 21.6 (6.6) 13.8 (6.9)*a,b,c
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functional status (ADL and iADL), and laboratory mea-
surements of HDL and TG (all P < 0.05), whilst daily fish
intake (p = 0.08) approached significance (Table 2).
Random effects modelling with longitudinal frailty score
as the outcome variable
We subsequently looked at longitudinal frailty scores via
the 3 cognitive subgroups at baseline, 6 months and
12 months (Fig. 3). We performed random effects mod-
elling with independent variables of age, gender, smoking
history, functional status (iADL), lifestyle factors (fish in-
take) and biochemical parameters (HDL and TG levels)
and longitudinal CDR-SB performance for the whole
group. Age (coeff 0.09, 95 % CI: 0.04–0.15, p = 0.001)
and cognition (CDR-SB) (coeff 0.04, 95 % CI: 0.02–0.07,
p = 0.000) were significantly associated with frailty score
(Table 3). When we performed random effects modelling
only on MCI subjects (n = 41), only female gender was
significantly associated with frailty score (coeff 1.28,
95 % CI 0.21–2.36, p = 0.019) (Table 4). Subsequent ana-
lyses with mild-moderate AD subjects (n = 81 showed
similar findings to whole group analyses where age (coeff
0.04, 95 % CI 0.02–0.07, p = 0.001) and cognition (coeff
0.11, 95 % CI 0.05–0.17, p = 0.000) remained signifi-
cantly associated with frailty score (Table 5).
We performed subgroup analyses on subgroup with
cognitive frailty (n = 18) and showed that those who pro-
gressed had more comorbidities (diabetes (4.0 compared
Table 1 Patient baseline demographics, vascular risk profile, cognitive and functional status among 3 cognitive subgroups (MCI,
mild AD and moderate AD) (Continued)
Nutrition, lean mass and functional performance
MNA total 13.0 (1.5) 13.2 (1.6) 13.0 (1.4) 12.7 (1.7)
Grip strength 19.5 (7.5) 22.7 (8.2) 18.3 (6.8) 16.3 (5.9)*b,c
SPPB total 8.7 (2.3) 9.7 (2.3) 8.9 (2.0) 6.5 (2.4)*b,c
Lean mass measurement (ALM/ht2) 6.6 (8.2) 6.2 (0.9) 6.9 (9.8) 5.5 (0.7)
Abbreviations: MCI mild cognitive impairment, AD Alzheimer’s disease, CDR, clinical dementia rating, CMMSE Chinese mini mental state examination (range 0–28),
HT hypertension, DM diabetes mellitus, IHD ischaemic heart disease, AF atrial fibrillation, PVD peripheral vascular disease, BMI, body-mass index, ETOH ethanol,
MDD diagnostic statistical manual definition of major depressive disorder, MTA medial temporal atrophy, ARWMC age-related white matter changes, ADL activities
of daily living (range 0–100), CG caregiver, activities of daily living (range 0–23), NPI neuropsychiatric Inventory, FAI frenchay activity index, MNA mini-nutritional
assessment, SPPB short physical performance battery, ALM/ht2 appendicular lean mass/ (height in metres) 2
*p < 0.05 between the 3 cognitive subgroups (ANOVA with Bonferroni correction for parametric and Kruskal-Wallis test for nonparametric continuous variables;
Chi-square test for categorical variables)
adifferences between mild and moderate AD
bdifferences between MCI and mild AD
cdifferences between MCI and moderate AD
Fig. 1 Frailty prevalence at baseline, 6 months and 12 months and cognitive scores at baseline and 12 months
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to 1.7 % unchanged and 0 % regressed); ischaemic heart
disease (33.3 compared to 66.7 % unchanged and 0 %
regressed)), less family support (children) (40 compared
to 60 % regressed), were functionally more impaired
(in terms of iADL) (12.3 ± 6.1, 20.4 ± 2.4 unchanged
and 18.7 ± 3.7 regressed ), had poorer performance on
chair stand test (1.0 ± 0, 4.0 ± 0 unchanged compared
to 2.7 ± 0.6 regressed) with paradoxically larger lean
muscle mass (6.8 ± 0.3 kg/m2 progressed, 5.1 ± 0 kg/m2
unchanged compared to 5.3 ± 0.4 kg/m2 regressed) (all
p < 0.05).
Discussion
The frailty syndrome has attracted attention as a poten-
tial therapeutic target due to its relation both as a pre-
cursor and contributor of disability in older persons.
More recently, experts have focused on cognitive frailty
[4, 5]. This is the first study to demonstrate frailty state
transitions over a one-year period in subjects with cogni-
tive impairment. It is important to note that these sub-
jects were near full independence in their basic ADLs
(Table 1), indicating that they were a cohort of relatively
well older adults in whom potential intervention could
result in reversibility of their conditions.
Contrary to expectations of increasing frailty with in-
creasing cognitive impairment, our previous published
work showed the U-shaped relationship between frailty
and increasing cognitive impairment, characterised by
the initial dissociation with cognitive impairment and
subsequent convergence at later stages [16]. These inter-
esting findings have been discussed in detail in the earl-
ier paper where these apparently contradictory
differences could be partially explained, or whether a
conceptual or measurement issue exists for the observed
differences in frailty prevalence. These observations re-
quire a larger sample size to confirm these conclusions.
Additionally, we suggested further research in the fatigue
sub-item in the biological frailty model to see if the fa-
tigue sub-item is driven by physical or psychological
components [16]. Our current results demonstrate con-
sistent results longitudinally. This is seen in the MCI
stage where longitudinal frailty status and scores now
show a linear decline over 12-month follow up, along
with almost one-third with frailty regression, which sup-
ports the potential reversibility of cognitive frailty. These
findings are further supported by random effects model-
ling results showing that in mild-moderate AD subjects,
cognitive changes (as shown by CDR-SB changes) and
age are directly associated with frailty progression while
in MCI subjects, gender and potentially other mecha-
nisms (unmeasured in this current study), may influence
physical frailty progression. Contrary to population study
findings, frailty progression in patients with established
cognitive impairment appears to be associated with age
and cognition, which supports the need for cognitive
therapies in those already with diagnosed dementia.
These initial findings also support cognitive frailty as a
significant and potentially modifiable entity whereby
frailty interventions may have a role in preventing phys-
ical and functional decline in cognitively impaired older
adults. Our study showed differential findings to other
community epidemiological studies [12] where female
gender was less likely to result in decline in frailty status
compared to men in MCI subjects (Table 4).
MCI remains a heterogeneous clinical construct with
different underlying pathological processes (neurode-
generation, vascular, mood, metabolic) when they
present in the clinical setting. In our study, we have
Fig. 2 Percentage of frailty transition status in the 3 cognitive subgroups (MCI, mild and moderate AD)
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Table 2 Comparison of baseline patient factors between 3 frailty transition states (n = 122)
Total (n-122) Regressed (n = 39) Unchanged (n = 44) Progressed(n = 39)
Demographics
Age 75.4 (7.1) 77.1 (6.9) 73.9 (7.2) 75.3 (7.1)
Gender (Male %) 40.1 38.5 36.4 46.2
Race (Chinese %) 94.3 92.3 97.7 92.3
Education years 7.1 (5.0) 6.6 (4.8) 7.3 (4.5) 7.3 (5.8)
CDR global 0.9 (0.5) 0.9 (0.5) 0.9 (0.4) 0.9 (0.5)
CDR Sum of boxes 4.0 (3.0) 4.6 (2.9) 3.8 (2.7) 3.6 (3.4)
CMMSE 20.0 (6.5) 19.2 (5.3) 20.9 (5.2) 20.1 (6.5)
Medical comorbidities
HT (%) 65.6 74.4 54.6 69.2
DM (%) 29.5 38.5 20.5 30.8
Hyperlipidemia (%) 70.5 66.7 70.5 74.4
IHD (%) 21.3 23.1 25.0 15.4
Smoker/ex-heavy smoker (%) 15.5 12.8 18.2 15.3 *
AF (%) 3.3 5.1 0.0 5.1
PVD (%) 0.8 2.6 0 0
Multimorbidity score 2.1 (1.2) 2.2 (1.2) 1.9 (1.2) 2.1 (1.3)
MDD (%) 2.5 2.6 2.3 2.6
Neurodegeneration and wm scores
APOE status
E2/e2 0.8 2.6 0 0
E2/e3 0.2 0.1 0.1 0
E2/e4 1.6 2.6 2.3 0
E3/e3 47.5 43.6 47.7 51.3
E3/e4 32.8 33.3 31.8 33.3
E4/e4 4.9 7.7 4.6 2.6
MTA score 1.2 (1.1) 1.2 (1.1) 1.3 (1.0) 1.2 (1.1)
ARWMC score 4.9 (4.2) 5.0 (5.2) 5.5 (4.1) 4.2 (3.1)
Function, behaviour and burden scores
ADL 97.8 (5.8) 95.9 (9.0) 99.0 (2.8) 98.5 (3.1)*a
iADL 15.7 (13.7) 13.7 (5.9) 16.5 (5.1) 16.8 (4.6) *a, b
NPI total severity 2.1 (1.7) 2.2 (1.8) 2.3 (1.9) 1.7 (1.3)
NPI CG distress 3.6 (5.3) 3.9 (6.0) 4.4 (5.5) 2.2 (3.9)
Zarit total 22.6 (16.1) 21.6 (12.6) 24.1 (19.8) 21.9 (14.7)
FAI total 22.9 (8.1) 21.0 (7.9) 24.9 (8.7) 22.7 (7.1)
Nutrition, lean mass and functional performance
MNA total 11.8 (1.4) 11.6 (1.2) 118 (1.6) 12.2 (1.4)
Grip strength 19.5 (7.5) 18.1 (7.3) 20.6 (8.0) 19.8 (7.1)
SPPB total 8.7 (2.3) 8.6 (2.1) 9.2 (2.2) 8.2 (2.6)
Lean mass measurement 6.6 (8.2) 8.0 (13.9) 5.9 (0.9) 5.8 (0.9)
Treatment
Donepezil 44.5 42.1 41.9 50.0
Galantamine 0 0 0 0
Rivastigmine 4.2 5.3 4.7 2.6
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shown that 16.7 % subjects with cognitive frailty (both
MCI and physical frailty) had frailty progression after
one year. The analyses of this small subgroup (n = 18)
showed that those who progressed had more comor-
bidities (diabetes, ischaemic heart disease), less family
support (children), were functionally more impaired
(in terms of iADL), had poorer performance on chair
stand test with paradoxically larger lean muscle mass
(results not shown). This seemed independent of the
APOEe4 status or neuro-degeneration measures of
medial temporal atrophy and ischaemic vascular le-
sions, which potentially add to further insights into
the differentiation of a physically driven process, com-
pared to a purely cognitive (neurodegeneration) driven
process [5, 39, 40]. These interesting findings (despite
a small sample size), requires further validation in fu-
ture carefully clinically-phenotyped subjects in larger
MCI studies.
Table 2 Comparison of baseline patient factors between 3 frailty transition states (n = 122) (Continued)
Memantine 22.7 34.2 25.6 7.9 *
Socioeconomic and lifestyle factors
Expenses
More than enough 34.4 60.1 44.4 63.0
Fair 37.5 33.3 44.4 29.6
Not enough 28.1 3.0 11.1 7.4
Lifestyle factors (%)
Daily Activities
1 + h 33.3 39.4 22.2 40.7
20-59 min 31.3 27.3 38.9 25.9
< 20 min 19.8 18.2 22.2 18.5
none 15.6 15.2 16.7 14.8
Vegetable and fruit intake (%)
Daily 83.3 78.8 86.1 85.2
< Daily 16.7 21.2 13.9 14.8
Fish intake (%)
Daily 41.7 30.3 55.6 37.0
< Daily 58.3 69.7 44.4 63.0 (p = 0.08)
Social support factors (%)
Neighbours
None 22.9 27.3 22.2 18.5
1-4 49.0 45.4 52.8 48.2
5-9 14.6 12.1 11.1 22.2
10+ 13.5 15.2 13.9 11.1
Laboratory investigations
Total chol 4.9 (1.1) 5.1 (1.1) 4.8 (1.2) 5.0 (0.9)
LDL 2.8 (0.9) 3.0 (1.0) 2.6 (0.9) 2.8 (0.8)
HDL 1.6 (0.7) 1.6 (0.5) 1.6 (0.7) 1.7 (0.7) *
TG 1.3 (0.7) 1.2 (0.7) 1.4 (0.9) 1.2 (0.5) *
Vit D level 30.3 (11.9) 29.5 (13.1) 29.6 (10.6) 32.1 (12.1)
Abbreviations: CDR clinical dementia rating, CMMSE Chinese mini mental state examination (range 0–28), HT hypertension, DM diabetes mellitus, IHD ischaemic
heart disease, AF atrial fibrillation, PVD peripheral vascular disease, BMI body-mass index, ETOH ethanol, MDD diagnostic statistical manual definition of major
depressive disorder, MTA medial temporal atrophy, ARWMC age-related white matter changes, ADL activities of daily living (range 0–100), CG caregiver; activities
of daily living (range 0–23), NPI neuropsychiatric inventory, FAI frenchay activity index, MNA mini-nutritional assessment, SPPB short physical performance battery,
LDL low-density lipoprotein, HDL high-density lipoprotein, TG triglyceride, Vit D Vitamin D
*p < 0.05 between the 3 frailty transition subgroups (ANOVA with Bonferroni correction for parametric and Kruskal-Wallis test for nonparametric continuous
variables; Chi-square test for categorical variables)
adifferences between frailty regressed and unchanged state
bdifferences between frailty regressed and progressed state
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The strengths of our study include the comprehensive
data available on both cognition and frailty measures.
However, we were limited by the relatively small sample
size and short follow-up period of one year. Other than
the current conventional laboratory measurements, we
had not included other biomarker measurements (such
as inflammatory and hormonal markers) in the current
paper, which might provide insights into the biological
underpinnings and further understanding of the com-
plex relationship between frailty and cognition [5].
Additionally, a matched control sample of healthy sub-
jects without cognitive impairment could have aided in
showing cognitive frailty is a separate entity, driving
frailty progression. A separate analyses (albeit a differ-
ent methodology) has suggested a concomitant pro-
inflammatory state without concomitant endocrine
deficiency, to adversely influence baseline and progres-
sive physical frailty [41].
Conclusion
In summary, this is the first study to demonstrate longi-
tudinal frailty state transitions in cognitively-impaired
older adults. Contrary to expectations of frailty progres-
sion to be closely correlated with increasing cognitive
impairment, they appear independent, especially in the
earliest stage of cognitive impairment. This study lends
Fig. 3 Frailty score at baseline, 6 month and 12 month for 3 cognitive subgroups (n = 122)
Table 3 The associations of the frailty score with the various
factors using the random effect model (whole group n = 122)
Coeff Std Err p-value 95 % Confidence interval
Frailty score
Age 0.04 0.012 0.000 0.02–0.07
Gender 0.22 0.18 0.224 −0.13–0.58
Smoking −0.01 0.23 0.964 −0.47–0.45
iADL −0.004 0.02 0.80 −0.04–0.03
Fish intake −0.03 0.15 0.84 −0.32–0.26
HDL −0.01 0.13 0.93 −0.27–0.24
TG 0.02 0.11 0.82 −0.19–0.24
CDR-SB 0.09 0.03 0.001 0.04–0.15
Abbreviations: Std Err standard error, iADL independent activities of daily living,
HDL high-density lipoprotein, TG triglyceride, CDR-SB clinical dementia rating
sum-of-boxes score
Table 4 The associations of the frailty score with the various
factors using the random effect model (MCI subjects n = 41)
Coeff Std Err p-value 95 % Confidence interval
Frailty score
Age 0.04 0.06 0.49 −0.07–0.16
Gender 1.28 0.55 0.02 0.21–2.36
Smoking 0.07 0.78 0.94 −1.50–1.62
iADL −0.10 0.08 0.22 −0.26–0.06
Fish intake 0.04 0.53 0.94 −0.99–1.08
HDL −0.05 0.30 0.86 −0.63–0.53
TG 0.33 0.54 0.55 −0.74–1.39
CDR-SB −0.31 0.39 0.43 −1.08–0.46
Abbreviations: Std Err standard error, iADL independent activities of daily living,
HDL high-density lipoprotein, TG triglyceride, CDR-SB clinical dementia rating
sum-of-boxes score
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initial support to ‘cognitive frailty’ entity being a poten-
tially modifiable factor for physical frailty progression. It
further allowed evidence for potential refinement of this
clinical construct for development of an ‘at-risk’ cogni-
tive frailty phenotype. Further research is needed with a
suitably powered study over a longer follow-up period
with additional focus on pathogenic mechanisms to
allow rapid translation of knowledge into useful thera-
peutic interventions.
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